18 results
8-K
EX-99.1
ZLAB
Zai Lab Limited
10 May 22
Zai Lab Announces First Quarter 2022
4:10pm
with niraparib compared to placebo: 24.8 months versus 8.3 months, hazard ratio (HR), 0.45; p<0.001. Other pre-specified efficacy results included … was 12.1 months, compared with 7.9 months for the matched-control patients in EF-14 (hazard ratio=0.46, p=0.033).
mOS was 25.2 months, compared with 15.9
8-K
EX-99.1
gtqg92 il
31 Mar 21
China NMPA Approves QINLOCK® (Ripretinib) for Treatment of Advanced Gastrointestinal Stromal
7:32am
10-K
EX-10.33
tlgielmjyelm
1 Mar 21
Annual report
12:00am
10-K
54ltojf 1fhz8d9
1 Mar 21
Annual report
12:00am
10-K
EX-10.32
vvgpl4j83q26my6pkp1r
1 Mar 21
Annual report
12:00am
6-K
EX-99.1
cama19muat5akcx
29 Dec 20
Zai Lab Announces Inclusion of ZEJULA® (Niraparib) in China’s National Reimbursement Drug List
7:30am
6-K
EX-99.1
d6e0z8doxjlmqjm
11 Sep 20
Zai Lab Limited Supplemental and Updated Disclosures
8:09am
6-K
EX-99.1
396i6 5nfj
10 Sep 20
Zai Lab Announces NMPA Approval of ZEJULA® (Niraparib) for First-Line Maintenance Treatment of Ovarian Cancer in China
7:35am
6-K
EX-99.1
1901w qui5oxl59a
20 Jul 20
China NMPA Accepts NDA Submission of Ripretinib for Advanced Gastrointestinal Stromal Tumor
7:35am
6-K
EX-99.1
7e7zszkpx1s9hb6 v2
27 Dec 19
Zai Lab Announces NMPA Approval of ZEJULA® (Niraparib) in China as Maintenance Therapy for Patients with Recurrent Ovarian Cancer
7:51am
6-K
EX-99.1
8zeauvttr1cxm uy2lu0
22 Oct 18
Zai Lab Announces Approval of ZEJULA® (Niraparib) for Patients with Relapsed Ovarian Cancer in Hong Kong
7:48am
20-F
vdwn3plm4wynn08dh7v
30 Apr 18
Annual report (foreign)
9:07am
- Prev
- 1
- Next